MAPK Pathway-Targeted Therapies: Care and Management of Unique Toxicities in Patients With Advanced Melanoma
Related Experiment Video
Updated: Feb 18, 2026
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
1Massachusetts General Hospital Cancer Center.
Background:
Agents targeting the MAPK pathway, including inhibitors of BRAF and MEK, have dramatically transformed the treatment landscape for patients with BRAF-mutant metastatic melanoma. Although generally well tolerated, targeted agents were associated with unique toxicities. .
Objectives:
This article aims to provide nurses with an overview of the key toxicities and associated management strategies of the characteristic adverse event (AE) profile associated with agents targeting the MAPK pathway. .
Methods:
Data from clinical trials evaluating vemurafenib, dabrafenib, trametinib, and cobimetinib were reviewed and summarized along with research on management of AEs identified in clinical trials. .
Findings:
The key AEs associated with these agents included pyrexia and cutaneous toxicities. Other notable AEs included arthralgias, ocular toxicities, and cardiac events. Because these agents are administered until progressive disease or unacceptable toxicity, nurses should be aware of management strategies to optimize treatment outcomes.
Insights
Nurses can manage unique toxicities like pyrexia and skin issues in patients receiving MAPK pathway inhibitors for metastatic melanoma. Awareness of adverse events (AEs) and management strategies optimizes treatment outcomes.
Area of Science:
- Oncology
- Pharmacology
- Dermatology
Background:
- Targeted therapies, including BRAF and MEK inhibitors, have revolutionized metastatic melanoma treatment.
- While effective, these agents present unique adverse event (AE) profiles requiring specialized nursing knowledge.
Purpose of the Study:
- To equip nurses with an understanding of key toxicities associated with MAPK pathway inhibitors.
- To outline management strategies for characteristic adverse events (AEs) in melanoma patients.
Main Methods:
- Review of clinical trial data for vemurafenib, dabrafenib, trametinib, and cobimetinib.
- Synthesis of research on managing identified adverse events (AEs).
Main Results:
- Key toxicities include pyrexia and cutaneous adverse events (AEs).
- Other significant AEs encompass arthralgias, ocular toxicities, and cardiac events.
- Management strategies are crucial as treatment continues until disease progression or toxicity.
Conclusions:
- Nurses play a vital role in managing AEs associated with MAPK pathway inhibitors.
- Effective AE management is essential for optimizing treatment outcomes in metastatic melanoma.
- Continuous education on AE profiles and interventions is recommended for oncology nurses.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy
01:07MAPK Signaling Cascades
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...